Silencing ROR2 inhibits metastatic behavior of ovarian cancer cells

2021 ◽  
Vol 162 ◽  
pp. S274
Author(s):  
Whitney Grither ◽  
Breanna Baker ◽  
Andrea Hagemann ◽  
Dineo Khabele ◽  
Lindsay Kuroki ◽  
...  
Oncotarget ◽  
2016 ◽  
Vol 7 (16) ◽  
pp. 21968-21981 ◽  
Author(s):  
Lana Bruney ◽  
Yueying Liu ◽  
Anne Grisoli ◽  
Matthew J. Ravosa ◽  
M. Sharon Stack

2018 ◽  
Author(s):  
F Guo ◽  
Z Yang ◽  
J Xu ◽  
J Sehouli ◽  
AE Albers ◽  
...  

2020 ◽  
Vol 19 (2) ◽  
pp. 206-210
Author(s):  
Feng Chen ◽  
Bei Zhang

Lupeol exhibits multiple pharmacological activities including, anticancerous, anti-inflammatory, and antioxidant. The aim of this study was to explore the anticancerous activity of lupeol on ovarian cancer cells and examine its mechanism of action. To this end, increasing concentrations of lupeol on cell viability, cell cycle, and apoptosis in Caov-3 cells were evaluated. Lupeol inhibited cell viability, induced G1 phase arrest in cell cycle, increased cell apoptosis, and inhibited the ratio of phospho-Akt/protein kinase B and phospho-mammalian target of rapamycin/mammalian target of rapamycin. In conclusion, these data suggest that lupeol may play a therapeutic role in ovarian cancer.


Sign in / Sign up

Export Citation Format

Share Document